EMMAC Life Sciences partner with Hyris to develop Unique Real-Time Phyto-Cannabinoid Rich technology for the specific identification of proprietary cultivars of Cannabis subsp.
June 24, 2019 Off

EMMAC Life Sciences partner with Hyris to develop Unique Real-Time Phyto-Cannabinoid Rich technology for the specific identification of proprietary cultivars of Cannabis subsp.

By BusinessWire

EMMAC, the European independent medical cannabis company, is pleased to announce an exclusive collaboration with Hyris Ltd, a UK-based biotechnology company, to develop a comprehensive library of genetic profiles of existing cannabis varieties, and to industrialise DNA-based methods for the identification of its unique branded cultivars.

Stoke Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
June 23, 2019 Off

Stoke Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

By BusinessWire

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company that is pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced the closing of its initial public offering of 9,074,776 shares of its common stock at a price to the public of $18.00 per share, which includes 1,183,666 shares sold upon full exercise of the underwriters’ option to purchase additional shares of common stock.